ZELBORAF (VEMURAFENIB) what is ZELBORAF Used for?

What is ZELBORAF approved for?

ZELBORAF is a medicine used to treat a type of skin cancer called melanoma that has spread to other parts of the body or cannot be removed by surgery, and contains a certain type of abnormal "BRAF" gene. Is.

Zelboraf is not used to treat melanoma with the normal BRAF gene.

Your healthcare provider will perform a test to make sure ZELBORAF is right for you.

ZELBORAF is a prescription medicine used to treat a type of blood cell cancer called Erdheim-Chester disease (ECD), which can affect the body's tissues and organs, and includes a certain type of abnormal "BRAF" "Gene is there.

It is not known whether Zelboraf is safe and effective in children under 18 years of age.

Important Safety Information

What is the most important information I should know about Zelboraf?

ZELBORAF can cause serious side effects, including:

New cancer risk. ZELBORAF may cause certain types of skin cancer called cutaneous squamous cell carcinoma (cuSCC) and keratoacanthoma. New lesions of melanoma have occurred in people taking ZELBORAF. ZELBORAF may also cause another type of cancer called non-cutaneous squamous cell carcinoma (non-QSCC). Talk to your healthcare provider about your risk for these cancers.

Check your skin and tell your healthcare provider right away about any skin changes, including:

  • ·         a new wart
  • ·         a sore or red bump in the skin that bleeds or does not heal
  • ·         change in size or color of the mole

Your healthcare provider should examine your skin before taking ZELBORAF, and every 2 months during treatment with ZELBORAF to look for any new skin cancers. Your healthcare provider may continue to examine your skin for up to 6 months after you stop taking ZELBORAF.

Your healthcare provider should also check for cancers that may not be on the skin. Tell your healthcare provider about any new symptoms you get while taking Zelboraf.

Other blood cancers have occurred in some people with Erdheim-Chester disease (ECD), including those taking Zelboraf. If you have other blood cancers and take ZELBORAF for ECD, your healthcare provider will monitor your blood cancer through regular blood tests.

Before taking ZELBORAF, tell your healthcare provider about all of your medical conditions, including if you:

  • ·         Have a heart problem, including a condition called Long QT syndrome
  • ·         have liver or kidney problems
  • ·         have received or are planning to have radiation therapy
  • ·         have been reported to have low levels of potassium, calcium, or magnesium in your blood
  • ·         Are pregnant or plan to become pregnant. Zelboraf may harm your unborn baby.

Women who are able to become pregnant should use effective birth control during treatment with ZELBORAF and for 2 weeks after the last dose of ZELBORAF.

Breast-feeding or planning to breast-feed. It is not known whether Zelboraf passes into your breast milk. Do not breast-feed during treatment with ZELBORAF and for 2 weeks after the last dose of ZELBORAF.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What should I avoid while taking Zelboraf vemurafenib?

Avoid sunlight during treatment with ZELBORAF. ZELBORAF can make your skin sensitive to sunlight. You can burn more easily and get a severe sunburn. To help protect against sunburn:

Wear clothing that protects your skin, including your head, face, arms, hands and feet, when you go out.

Use lip balm and broad-spectrum sunscreen with SPF 30 or higher.

What are the possible side effects of Zelboraf?

You could have an allergic reaction while taking ZELBORAF, and it could be serious. If you get any of these allergy symptoms, stop taking Zelboraf and get medical help right away:

  • ·         rash or redness all over your body
  • ·         trouble breathing or swallowing
  • ·         swelling of the face, lips, or tongue
  • ·         sore throat or hoarseness
  • ·         feel faint
  • ·         fast heartbeat

Serious skin reactions. If you get a skin rash with any of the following symptoms, stop taking Zelboraf and call your healthcare provider right away, as you may have a serious skin reaction:

  • ·         blisters on your skin
  • ·         sores or sores in your mouth
  • ·         peeling of your skin
  • ·         fever
  • ·         redness or swelling of your face, hands, or the soles of your feet
  • ·         your heart's electrical activity

Location: New Delhi, Delhi, India

Comments

Post a Comment

Popular posts from this blog

What Is IDHIFA (Enasidenib)? Causes, Side Effects, Dosage

Image
  WHAT IS IDHIFA (Enasidenib)? IDHIFA Medicine IDHIFA is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not improved after previous treatment(s). It is not known if IDHIFA is safe and effective in children. IDHIFA may cause serious side effects, including: Differentiation Syndrome. Differentiation syndrome is a condition that affects your blood cells which may be life-threatening or lead to death if not treated. Differentiation syndrome has happened within 1 day and up to 5 months after starting IDHIFA. Check the following symptoms below. ·          fever ·          cough ·          shortness of breath ·          swelling of arms and legs ·          fast weight gain (greater than 10 pounds within a week) ·          bone pain If you develop any of these symptoms of differentiation syndrome, your healthcare provider may start you on a medicine taken by m
Read more

Hunter Syndrome is Very Rare | Named Patient Program in India

Image
  Hunter Syndrome is an extremely uncommon, acquired hereditary problem brought about by an absent or breaking down compound. In Hunter disorder, the body needs more of the compound iduronate 2-sulfatase. This present compound's responsibility is to separate specific complex particles, and without enough of this protein, the atoms develop in unsafe sums.  The development of enormous measures of these unsafe substances in the long run causes long-lasting, moderate harm influencing appearance, mental turn of events, organ work and actual capacities. Hunter Syndrome is undeniably more normal in young men. The condition is one kind of a gathering of acquired metabolic issues called mucopolysaccharidoses (MPSs). Tracker condition is otherwise called MPS II. Import Elaprase (idursulfase) medicine under named patient program which is commonly use for hunter syndrome.  There's no remedy for Hunter disorder. Treatment includes overseeing side effects and difficulties. Side effects Syndr
Read more

Glyxambi (empagliflozin and linagliptin) Medicine - Uses, Precautions, Indications

Image
What is Glyxambi? Glyxambi (empagliflozin and linagliptin) is a combination of an inhibitor of the sodium-glucose co-transporter (SGLT2) and an inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme as an adjunct to diet and exercise to improve glycemic control. What are the side effects of Glyxambi? Common side effects of Glyxambi include: • urinary tract infection • Common cold symptoms • Upper respiratory tract infection • Genital Yeast Infection • Increased urination • Joint pain • Nausea • runny or stuffy nose • Diarrhea • cough • Elevated blood cholesterol or fat • Diarrhea Glyxambi Dosage The recommended dose of Glyxambi is 10 mg empagliflozin/5 mg linagliptin, taken once daily in the morning, with or without food. In patients who tolerate Glyxambi, the dose may be increased to 25 mg empagliflozin/5 mg linagliptin once daily. Do drugs, substances, or supplements interact with Glyxambi? Glyxambi during pregnancy and lactation During pregnancy
Read more